Which P-CAB generic will come first, K-CAB or Vocinti?
By Lee, Tak-Sun | translator Kim, Jung-Ju
23.09.14 16:19:59
가나다라
0
Bioequivalence tests have been conducted with the two drugs as comparators this year
K-CAB generic seeks release in December 2026, the release will depend on whether companies can avoid K-CAB’s patent
gastroesophageal reflux disease (GERD) treatments K-CAB (tegoprazan, HK Inno.N) and Vocinti (vonoprazan, Takeda Pharmaceuticals Korea).
The post-marketing surveillance (PMS) period for the original drugs, which are being targeted by the generic companies, is set to end in 2024 and 2025, respectively. The release of their generic versions will then depend on whether they can avoid the originals’ patents.
According to industry sources on the 14th, approvals for bioequivalence tests using K-CAB and Vocinti as reference drugs have been continuing this year.
In
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)